Cargando…
BJTJ-1837, a novel FXI activation-blocking antibody
BACKGROUND: Factor (F)XI contributes to thrombosis development while it plays a limited role in normal hemostasis. FXI targeting has the potential for preventing and treating thrombosis with little bleeding risk. OBJECTIVES: The aim of this study was to develop novel antibody therapeutics against FX...
Autores principales: | He, Xugang, Zhang, Jin, Du, Yanping, Liu, Xiao, Hu, Dongmei, Cao, Baohua, Gao, Hong, Wu, Yongguang, Zhou, Tianlin, Wu, Qimei, Huang, Qi, Yang, Changyong, Liao, Cheng, Zhang, Lianshan, Shen, Chenxi, Wang, Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017418/ https://www.ncbi.nlm.nih.gov/pubmed/36936858 http://dx.doi.org/10.1016/j.rpth.2023.100067 |
Ejemplares similares
-
Analysis of 272 Genetic Variants in the Upgraded Interactive FXI Web Database Reveals New Insights into FXI Deficiency
por: Harris, Victoria A., et al.
Publicado: (2021) -
Anticoagulant therapy in patients with congenital FXI deficiency
por: Bravo-Pérez, Carlos, et al.
Publicado: (2021) -
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
por: Willmann, Stefan, et al.
Publicado: (2021) -
Model‐dependent contributions of FXII and FXI to venous thrombosis in mice
por: Grover, Steven P., et al.
Publicado: (2020) -
P1681: FXI LEVELS AS INDEPENDENT RISK FACTOR FOR THROMBOSIS/OBSTETRIC EVENTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES
por: De La Morena-Barrio, M. E., et al.
Publicado: (2022)